Institut fuer Klinische Krebsforschung IKF GmbH
- Address
- Steinbacher Hohl 2-26, Praunheim, 60488 Frankfurt, Germany
Metastatic EGFR‑mutated NSCLC
The site focuses on non‑small cell lung cancer driven by EGFR mutations, aiming to improve outcomes for patients whose disease has progressed after standard targeted therapy.
- Targeted therapy for EGFR‑mutated lung cancer
- Antibody‑drug conjugates in oncology
- Progression‑free survival as a key efficacy measure
Institut fuer Klinische Krebsforschung IKF GmbH in Frankfurt conducts these studies with two dedicated investigators, exploring new treatment options beyond platinum‑based chemotherapy.
KRAS G12C‑mutated Advanced Colorectal Cancer
Research at the centre addresses colorectal cancer with the KRAS G12C mutation, testing a novel KRAS inhibitor in combination with an EGFR antibody to enhance second‑line therapy effectiveness.
- KRAS‑targeted agents in colorectal cancer
- Combination strategies with cetuximab
- Second‑line treatment options for advanced disease
The Frankfurt‑based institute leverages its pharmaceutical expertise and two investigators to evaluate innovative approaches that may extend survival for patients with limited options.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 1 therapeutic areas and 15 of 16 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Institut fuer Klinische Krebsforschung IKF GmbH
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Phase 3 Randomized Study of Adagrasib and Cetuximab Versus Chemotherapy in Advanced Colorectal Cancer with KRAS G12C Mutation Post-First-Line Therapy | Mirati Therapeutics Inc. | Phase III | Not Recruiting | Nov 2021 | — |
IMP list
lock Showing 1 of 16 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cetuximab | 2 | Unknown | 2021-11-30 | 2021-11-30 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.